MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Suletud

SektorTervishoid

81.62 1.22

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

79.04

Max

81.76

Põhinäitajad
By Trading Economics
Sissetulek	26M 54M
Müük	23M 407M
P/E Sektori keskmine	22.255 66.418
Kasumimarginaal	13.296
Töötajad	1,193
EBITDA	31M 98M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+15.81% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-51M 4.9B
Eelmine avamishind	80.4
Eelmine sulgemishind	81.62

Uudiste sentiment

By Acuity

21%

79%

45 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

79.24 / 103.64 Toetus ja vastupanu

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. apr 2026, 23:25 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. apr 2026, 22:45 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. apr 2026, 18:03 UTC

Tulu

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. apr 2026, 23:58 UTC

Tulu

Review & Preview: Earnings Time -- Barrons.com

13. apr 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. apr 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. apr 2026, 23:01 UTC

Tulu

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. apr 2026, 23:01 UTC

Tulu

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. apr 2026, 23:01 UTC

Tulu

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. apr 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. apr 2026, 21:26 UTC

Uudisväärsed sündmused

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. apr 2026, 21:23 UTC

Tulu

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. apr 2026, 21:16 UTC

Tulu

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

13. apr 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. apr 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. apr 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. apr 2026, 19:27 UTC

Market Talk

Uudisväärsed sündmused

Correction to Precious Metals Market Talk on April 9

13. apr 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk

Uudisväärsed sündmused

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk

Uudisväärsed sündmused

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. apr 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

15.81% tõus

12 kuu keskmine prognoos

Keskmine 93.33 USD 15.81%

Kõrge 110 USD

Madal 85 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

79.24 / 103.64Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

45 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.